Viking Therapeutics/$VKTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Ticker
$VKTX
Sector
Primary listing
Employees
49
Headquarters
Website
VKTX Metrics
BasicAdvanced
$2.7B
-
-$1.54
0.62
-
Price and volume
Market cap
$2.7B
Beta
0.62
52-week high
$74.15
52-week low
$18.92
Average daily volume
8.2M
Financial strength
Current ratio
25.86
Quick ratio
25.257
Long term debt to equity
0.052
Total debt to equity
0.11
Interest coverage (TTM)
-2,217.05%
Profitability
Management effectiveness
Return on assets (TTM)
-14.99%
Return on equity (TTM)
-19.99%
Valuation
Price to book
3.35
Price to tangible book (TTM)
3.35
Price to free cash flow (TTM)
-17.337
Free cash flow yield (TTM)
-5.77%
Free cash flow per share (TTM)
-1.366
Growth
Earnings per share change (TTM)
64.31%
3-year earnings per share growth (CAGR)
26.33%
10-year earnings per share growth (CAGR)
-4.36%
What the Analysts think about VKTX
Analyst ratings (Buy, Hold, Sell) for Viking Therapeutics stock.
Bulls say / Bears say
VK2735 demonstrated up to 12.2% body weight reduction over 13 weeks in a mid-stage Phase 2a trial, aligning its efficacy with top oral obesity treatments. (Reuters)
Oral weight-loss drugs like VK2735 are expected to capture significant share of a projected $150 billion market due to their ease of administration compared to injectables. (Reuters)
The multi-year manufacturing agreement with CordenPharma secures dedicated capacity for multi-ton API supply, 100 million injectors, and over 1 billion tablets annually, mitigating critical supply chain risks ahead of commercialization. (Fierce Pharma)
A 20% discontinuation rate in the VK2735 trial versus 13% for placebo, driven by gastrointestinal side effects, spurred a nearly 35% premarket share decline, underscoring tolerability concerns. (Reuters)
Competing oral obesity treatments from Eli Lilly and Novo Nordisk have demonstrated similar or superior efficacy in longer-duration studies, intensifying competitive pressure on VK2735’s market differentiation. (Reuters)
Cash reserves declined by $51 million from $903 million to $852 million in Q1 2025, reflecting elevated R&D and manufacturing expenditures that may necessitate additional financing. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
VKTX Financial Performance
Revenues and expenses
VKTX Earnings Performance
Company profitability
VKTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Viking Therapeutics stock?
Viking Therapeutics (VKTX) has a market cap of $2.7B as of September 18, 2025.
What is the P/E ratio for Viking Therapeutics stock?
The price to earnings (P/E) ratio for Viking Therapeutics (VKTX) stock is 0 as of September 18, 2025.
Does Viking Therapeutics stock pay dividends?
No, Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Viking Therapeutics dividend payment date?
Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Viking Therapeutics?
Viking Therapeutics (VKTX) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.